GeoMet, Inc. (OTCMKTS:GMET) announced on 5 march that its Board of Directors has declared a quarterly dividend to its preferred stockholders covering the period January 1, 2014 through March 31, 2014 to be paid through the issuance of .03125 preferred share (“PIK Preferred Shares”) per outstanding share of preferred stock. GeoMet Inc. (OTCMKTS:GMET) shares after opening at $0.01 moved to $0.01 on last trade day and at the end of the day closed at $0.0150. Company price to sales ratio in past twelve months was calculated as 0.02 and price to cash ratio as 0.76. GeoMet Inc. (OTCMKTS:GMET) showed a negative weekly performance of -25.00%.
UBS AG cut shares of Basic Sanitation Company of the State of Sao Paulo SABESP (NYSE:SBS) from a neutral rating to a sell rating in a research report sent to investors on Thursday morning, TheFlyOnTheWall.com reports. Companhia de Saneamento Basico (ADR) (NYSE:SBS) shares advanced 1.31% in last trading session and ended the day on $8.50. SBS return on equity ratio is recorded as 17.60% and its return on assets is 7.80%. Companhia de Saneamento Basico (ADR) (NYSE:SBS) yearly performance is -41.18%.
McLean Capital Management upgraded shares of VirnetX Holding Corp. (NYSE:VHC) from a sell rating to a neutral rating in a research report sent to investors on Friday morning, Analyst Ratings Network reports. VirnetX Holding Corporation (NYSEMKT:VHC) shares moved down -2.21% in last trading session and was closed at $14.14, while trading in range of $13.86 – $14.50. VirnetX Holding Corporation (NYSEMKT:VHC) year to date (YTD) performance is -27.15%.
Ventrus Biosciences Inc. (NASDAQ:VTUS) on Feb. 12 announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). Ventrus Biosciences Inc. (NASDAQ:VTUS) weekly performance is 0.72%. On last trading day company shares ended up $1.39. Ventrus Biosciences Inc. (NASDAQ:VTUS) distance from 50-day simple moving average (SMA50) is -48.20%. Analysts mean target price for the company is $2.50.